The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics

威罗菲尼 最大值 药代动力学 医学 交叉研究 餐食 耐受性 药理学 内科学 不利影响 转移性黑色素瘤 癌症 安慰剂 病理 替代医学
作者
Antoni Ribas,Weijiang Zhang,Ilsung Chang,Keisuke Shirai,Marc S. Ernstoff,Adil Daud,C. Lance Cowey,Gregory A. Daniels,Elizabeth Seja,Elizabeth O'Laco,John A. Glaspy,Bartosz Chmielowski,Todd Hill,Andrew K. Joe,Joseph F. Grippo
出处
期刊:The Journal of Clinical Pharmacology [Wiley]
卷期号:54 (4): 368-374 被引量:42
标识
DOI:10.1002/jcph.255
摘要

The Journal of Clinical PharmacologyVolume 54, Issue 4 p. 368-374 Editor's Choice The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics Antoni Ribas MD, PhD, Antoni Ribas MD, PhD Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USASearch for more papers by this authorWeijiang Zhang PhD, Weijiang Zhang PhD F. Hoffman-La Roche, Nutley, NJ, USASearch for more papers by this authorIlsung Chang MD, PhD, Ilsung Chang MD, PhD Genentech, Inc., South San Francisco, CA, USASearch for more papers by this authorKeisuke Shirai MD, Keisuke Shirai MD Medical University of South Carolina, Charleston, SC, USASearch for more papers by this authorMarc S. Ernstoff MD, Marc S. Ernstoff MD Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, NH, USASearch for more papers by this authorAdil Daud MBBS, Adil Daud MBBS University of California, San Francisco, CA, USASearch for more papers by this authorC. Lance Cowey MD, C. Lance Cowey MD Texas Oncology–Baylor Charles A. Sammons Cancer Center, Dallas, TX, USASearch for more papers by this authorGregory Daniels MD, Gregory Daniels MD University of California, San Diego, La Jolla, CA, USASearch for more papers by this authorElizabeth Seja MD, Elizabeth Seja MD Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USASearch for more papers by this authorElizabeth O'Laco, Elizabeth O'Laco Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USASearch for more papers by this authorJohn A. Glaspy MD, John A. Glaspy MD Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USASearch for more papers by this authorBartosz Chmielowski MD, PhD, Bartosz Chmielowski MD, PhD Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USASearch for more papers by this authorTodd Hill MD, MS, Todd Hill MD, MS F. Hoffman-La Roche, Nutley, NJ, USASearch for more papers by this authorAndrew K. Joe MD, Andrew K. Joe MD F. Hoffman-La Roche, Nutley, NJ, USASearch for more papers by this authorJoseph F. Grippo PhD, Corresponding Author Joseph F. Grippo PhD F. Hoffman-La Roche, Nutley, NJ, USA Corresponding Author: Joseph F. Grippo, F. Hoffman-La Roche, 340 Kingsland Street, Nutley, NJ 07110, USA Email: [email protected]Search for more papers by this author Antoni Ribas MD, PhD, Antoni Ribas MD, PhD Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USASearch for more papers by this authorWeijiang Zhang PhD, Weijiang Zhang PhD F. Hoffman-La Roche, Nutley, NJ, USASearch for more papers by this authorIlsung Chang MD, PhD, Ilsung Chang MD, PhD Genentech, Inc., South San Francisco, CA, USASearch for more papers by this authorKeisuke Shirai MD, Keisuke Shirai MD Medical University of South Carolina, Charleston, SC, USASearch for more papers by this authorMarc S. Ernstoff MD, Marc S. Ernstoff MD Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, NH, USASearch for more papers by this authorAdil Daud MBBS, Adil Daud MBBS University of California, San Francisco, CA, USASearch for more papers by this authorC. Lance Cowey MD, C. Lance Cowey MD Texas Oncology–Baylor Charles A. Sammons Cancer Center, Dallas, TX, USASearch for more papers by this authorGregory Daniels MD, Gregory Daniels MD University of California, San Diego, La Jolla, CA, USASearch for more papers by this authorElizabeth Seja MD, Elizabeth Seja MD Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USASearch for more papers by this authorElizabeth O'Laco, Elizabeth O'Laco Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USASearch for more papers by this authorJohn A. Glaspy MD, John A. Glaspy MD Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USASearch for more papers by this authorBartosz Chmielowski MD, PhD, Bartosz Chmielowski MD, PhD Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USASearch for more papers by this authorTodd Hill MD, MS, Todd Hill MD, MS F. Hoffman-La Roche, Nutley, NJ, USASearch for more papers by this authorAndrew K. Joe MD, Andrew K. Joe MD F. Hoffman-La Roche, Nutley, NJ, USASearch for more papers by this authorJoseph F. Grippo PhD, Corresponding Author Joseph F. Grippo PhD F. Hoffman-La Roche, Nutley, NJ, USA Corresponding Author: Joseph F. Grippo, F. Hoffman-La Roche, 340 Kingsland Street, Nutley, NJ 07110, USA Email: [email protected]Search for more papers by this author First published: 28 December 2013 https://doi.org/10.1002/jcph.255Citations: 39 Clinical trial registration number NCT01264380. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract Vemurafenib is an orally bioavailable BRAF inhibitor approved for the treatment of BRAFV600-mutant metastatic melanoma. It is important to understand the effects of a high-fat meal on the pharmacokinetics (PK) of vemurafenib in humans because it is a Biopharmaceutics Classification System Class IV drug and its PK can be altered by food. An open-label, multicenter, randomized, 2-period crossover study was performed to evaluate the effect of food (high-fat meal) on the PK of a single oral dose of vemurafenib. Secondary objectives were safety and tolerability, efficacy with best overall response rate, and overall survival during the treatment period. The concomitant intake of food (high-fat meal) increased mean Cmax 3.5 to 7.5 µg/mL and mean AUC0−∞ 119 to 360 µg·h/mL after a single 960 mg dose of vemurafenib (N = 13–15 patients). An effect of food on single-dose exposure is suggested by point estimates and 90% CI of geometric mean ratios for vemurafenib plasma AUC0−∞ (4.7) and Cmax (2.5). Toxicity and response rate of vemurafenib in this study were consistent with prior experience in patients with BRAFV600-mutant metastatic melanoma. A high-fat meal increased the exposure to vemurafenib without altering the mean terminal half-life. References 1 Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949–954. 2 Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007; 445: 851–857. 3 Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010; 467: 596–599. 4 Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363: 809–819. 5 Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366: 707–714. 6 Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507–2516. 7 Shah N, Iyer RM, Mair HJ, et al. Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process. J Pharm Sci. 2013; 102: 967–981. 8 Grippo JF, Zhang W, Heinzmann D, et al. A phase I, randomized, open-label, study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF (V600E) mutation–positive metastatic melanoma. Cancer Chemother Pharmacol. 2014; 73: 103–111. 9 Winstanley PA, Orme ML. The effects of food on drug bioavailability. Br J Clin Pharmacol. 1989; 28: 621–628. 10 Koskimies P, Katila K, Lammintausta R, et al. Oral bioavailability of ospemifene improves with food intake. Int J Clin Pharmacol Ther. 2013; 51: 787–794. 11 Kiang TKL, Wilby KJ, Ensom MHH. Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions. Clin Pharmacokinet. 2013; 52: 487–510. Citing Literature Volume54, Issue4April 2014Pages 368-374 ReferencesRelatedInformation
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zyfzyf发布了新的文献求助10
刚刚
easymoney发布了新的文献求助10
刚刚
bkagyin应助dudu采纳,获得10
刚刚
同城代打发布了新的文献求助10
1秒前
小陈发布了新的文献求助10
1秒前
缥缈小熊猫完成签到,获得积分10
1秒前
1秒前
2秒前
灰色与青完成签到,获得积分10
2秒前
3秒前
Cathy完成签到,获得积分10
3秒前
3秒前
守护星星发布了新的文献求助10
3秒前
3秒前
驿路梨花发布了新的文献求助30
4秒前
daniel完成签到,获得积分10
4秒前
yznfly应助卷毛的好青年采纳,获得30
5秒前
5秒前
easymoney完成签到,获得积分10
5秒前
xiaojin完成签到,获得积分10
6秒前
弓長玉王令完成签到 ,获得积分10
6秒前
xue完成签到,获得积分10
6秒前
星辰大海应助无昵称采纳,获得10
6秒前
星星发布了新的文献求助10
7秒前
优雅采文发布了新的文献求助10
7秒前
安之若素完成签到,获得积分10
7秒前
金金发布了新的文献求助10
7秒前
执笔完成签到,获得积分10
7秒前
畅快访蕊完成签到,获得积分10
8秒前
8秒前
8秒前
嗜血啊阳完成签到,获得积分10
8秒前
8秒前
8秒前
8秒前
量子星尘发布了新的文献求助10
9秒前
9秒前
胡萝卜发布了新的文献求助10
9秒前
言午发布了新的文献求助200
9秒前
111完成签到 ,获得积分10
11秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969222
求助须知:如何正确求助?哪些是违规求助? 3514124
关于积分的说明 11171948
捐赠科研通 3249361
什么是DOI,文献DOI怎么找? 1794799
邀请新用户注册赠送积分活动 875431
科研通“疑难数据库(出版商)”最低求助积分说明 804779